Compare ADPT & NSIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | NSIT |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.1B |
| IPO Year | 2019 | 1996 |
| Metric | ADPT | NSIT |
|---|---|---|
| Price | $27.73 | $150.97 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | $33.86 | ★ $177.50 |
| AVG Volume (30 Days) | ★ 2.1M | 463.7K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ 4.28 |
| Revenue | $276,976,000.00 | ★ $8,247,180,000.00 |
| Revenue This Year | $10.85 | $12.22 |
| Revenue Next Year | $21.60 | $4.75 |
| P/E Ratio | ★ N/A | $37.49 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $12.00 | $63.62 |
| 52 Week High | $32.21 | $182.12 |
| Indicator | ADPT | NSIT |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 40.17 |
| Support Level | $24.02 | $150.99 |
| Resistance Level | $29.92 | $163.53 |
| Average True Range (ATR) | 1.71 | 8.85 |
| MACD | -0.09 | -1.83 |
| Stochastic Oscillator | 31.91 | 2.65 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.